Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure
JACC: Heart Failure · 2025-12 · 13 (12) · 102452
DOI: 10.1016/j.jchf.2025.02.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JACC: Heart Failure, 2025-12. Verfasst von Bertram Pitt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA. Electronic address: bpitt@med.umich.edu. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Heart Failure, Hypertension. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Mineralocorticoid receptor antagonists (MRAs) reduce cardiovascular mortality and heart failure (HF) hospitalizations across the spectrum of HF. Beyond their recognized benefits in patients with established HF, the value of MRA therapy may be undervalued for the prevention of HF in patients with hypertension. Emerging evidence indicates that a substantial proportion of patients considered to have "idiopathic" or "essential" hypertension have mineralocorticoid receptor overactivation by under-recognized mechanisms (such as, primary aldosteronism pathophysiology, cortisol dysregulation, and ligand-independent activation). The recognition that MRAs may address an operative mechanism of HF pathogenesis, and that implementation of therapy early in the course of hypertension may prevent the incidence of HF, suggests a new strategy to prevent HF that warrants further investigation. This review summarizes new evidence and theories which suggest that increased use of MRAs in hypertension may decrease incident HF by addressing common and under-recognized mechanisms of mineralocorticoid receptor overactivation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA. Electronic address: bpitt@med.umich.edu.
- Center for Adrenal Disorders, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: anandvaidya@bwh.harvard.edu.
Zitieren
APA
Pitt, B., & Vaidya, A. (2025). Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure. JACC: Heart Failure, 13(12), 102452. https://doi.org/10.1016/j.jchf.2025.02.021
Vancouver
Pitt B, Vaidya A. Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure. JACC: Heart Failure. 2025;13(12):102452. doi:10.1016/j.jchf.2025.02.021
BibTeX
@article{Pitt2025,
author = {Pitt, Bertram and Vaidya, Anand},
title = {Mineralocorticoid Receptor Antagonist Use in Hypertension to Prevent Heart Failure},
journal = {JACC: Heart Failure},
year = {2025},
volume = {13},
number = {12},
pages = {102452},
doi = {10.1016/j.jchf.2025.02.021}
}
EUVIMED